Royal Pharmaceutical Society website help

Our help system is designed to help you with using the features of the Royal Pharmaceutical Society's website.

  • 15/01/2017




Last updated 2 years ago



(Enter the content of this article below)



Downloading the app

You can download the app from the Google Play and Apple iTunes stores.

RPharmS-iRx is designed to work on iPhone 4+ and iPad 2+ (including iPad Mini) on iOS7 and above, or Android devices running 4.0 (Ice Cream Sandwich) and above.

Opening the app for the first time

Once you have downloaded the app on your mobile device and open it for the first time you will be prompted to ensure you have a back-up facility activated on your phone, such as iCloud, or that you are manually backing-up your smartphone/tablet regularly. This is to ensure that your data is not lost accidentally, should you lose or reset your device.

You will then be prompted to login in using your Royal Pharmaceutical Membership number and surname. When entering your surname, please make sure to type it correctly as this field is case-sensitive e.g. 'Jones' rather than 'jones'.
If you experience issues logging in, please log in to the website first and verify your details in My Profile.

You can sign out of the app later by going to the 'Settings' screen.

Using RPharmS-iRx

The RPharmS-iRx app contains a formulary of editable drug templates. The list has been populated with the 200 most commonly prescribed and specialist medicines across primary and secondary care. You can view an alphabetical list of these medicines from the 'Drugs' screen. You can also access this list from the 'Drug category' screen.

An 'S' next to a drug name denotes a specialist medicine. You can add new drugs by clicking the + symbol on the Drugs screen.

How to populate a drug template

When you click on a drug you will see a list of editable sections,

including BRAINS&AIMS - you can add text notes, images, web links or

voice notes to each of these areas:

  • Pharmacology
    Mechanism of action, pharmacodynamics, pharmacokinetics, chemistry, physicochemical properties. Compare these parameters with other drugs within the same class.
  • Indications
    Include both licensed and unlicensed indications, any local formulary considerations could be added here.
  • Benefits
    Which patients or conditions will benefit from this drug and how much will they benefit. Include information from key publications on how much benefit a patient is expected to experience. Think about the level of evidence available for this drug for a particular indication.
  • Risks
    This section could include some risk vs benefit information. What harm might come to your patient, their carer, or the general population?
  • Adverse effects
    Common and serious adverse effects of the drug. For each reaction you could describe how they can be prevented or treated and whether they are dose-dependent and how they should be reported.
  • Interactions
    Common and serious drug interactions. The interactions may be pharmacokinetic and/or pharmacodynamics, and may be beneficial or detrimental, and antagonistic or synergistic. Describe how the interaction should be managed or whether it should be avoided completely.
  • Necessary prophylaxis
    This section should contain details about any prophylaxis that may need to be prescribed with this drug to help prevent or reduce the severity of adverse effects.
  • Susceptible groups
    This section should contain information about patient groups or conditions that may respond differently to this drug (see cautions and contra-indications in the BNF). Think about Age, Sex, Diseases (e.g. renal or hepatic), Genetic, Altered physiology, Pregnancy and Breast-feeding.
  • Administering
    This section should contain information regarding the methods by which the drug can be administered. Think about I-DRAFFT: ID drug, patient, Doses (starting dose, titration regimens), Routes (when might each route be used, dose conversions between preparations), Allergy-check, Formulation, Frequency and Timing (pharmacokinetics, half-lives, missed doses, and overdoses). What are the parenteral administration requirements e.g. concentration, volume, rate and duration? Are there compatibility issues (solvent, other drugs)? How should the drug be administered to a patient that is not swallowing? What action should be taken if a patient misses a dose, or takes too much?
  • Informing
    What information should be discussed regarding this drug with the patient, carer, relatives, nurses, pharmacists, doctors. Reflect on the other BRAINS and AIMS.
  • Monitoring
    This section should contain details about the parameters that should be monitored in the patient to detect beneficial and adverse effects. These may be both subjective and objective, and may be from a variety of sources e.g. clinical, biochemical, haematological. Think about whether this drug requires therapeutic drug monitoring (TDM: PK/PD, timing, interpretation and dose adjustment). Are there any equations that can be used to help interpret dose and provide details of dosage adjustments?
  • Stopping
    Identify appropriate duration of treatment and reasons for stopping (monitoring) or importance of not stopping and special precautions for stopping.

Sharing templates

You can share your drug template via email direct from the app, simply click the Share button in the top right hand corner.

No sections defined